AOD-9604 Reconstitution: Water per Vial, mg/mL and Units

How 2 mg, 5 mg and 10 mg AOD-9604 vials convert to mg/mL and U-100 units for the 300 to 500 mcg figures protocol pages state, beside the oral trial doses.

Medibact Guides · Published 2026-09-18

Illustration: An empty insulin syringe resting on a white surface, bathed in soft, even light. — Illustration

AOD-9604 is a synthetic version of a short piece of human growth hormone, the region at residues 176 to 191, with a tyrosine added. Its developers tested it as an oral obesity drug in the early 2000s; today it is sold as a research powder in 2 mg, 5 mg and 10 mg vials, the sizes the AOD-9604 calculator carries. This page reports the water volumes the sources state, the concentration each produces, and what the microgram figures those sources quote come to on a U-100 syringe, next to the oral doses the human trials actually used. It reports and does not recommend. The figures and their provenance are on the AOD-9604 dosage page; every compound's arithmetic is indexed on the reconstitution hub.

What the sources state

Source	What it states	Kind of source	Opened
DailyMed search, "AOD-9604"	Zero labels	Regulator database	2026-09-18
ClinicalTrials.gov, "AOD-9604" and "AOD9604" as intervention	No studies	Trial registry	2026-09-18
PubMed	22 records with either spelling in title or abstract, 18 tagged for humans; no primary results publication of the obesity trials	Literature database	2026-09-18
Moré and Kenley, J Endocrinol Metab 2014	"Six human clinical trials ... including two intravenous (IV) and two oral dosing pilot studies. Two oral phase IIb studies with 300 and 500 obese adults"; GRAS status for food use	Peer-reviewed review by the developers	2026-09-18
News-Medical, 2004-12-16	Company announcement: 300 obese patients, oral 1, 5, 10, 20 or 30 mg or placebo once daily, 12 weeks; the 1 mg group lost 2.8 kg against 0.8 kg on placebo	News report of a company announcement	2026-09-18
BioSpace, 2006-10-05	Company announcement: OPTIONS study, 536 subjects, oral 0.25, 0.5 or 1 mg daily or placebo, 24 weeks; results expected March 2007	Company announcement	2026-09-18
Peptide Dosing Protocols, AOD-9604 guide	5 mg in 3 mL, about 1,667 mcg/mL, "1 unit on a U-100 syringe is roughly 16.67 mcg"; "300 to 500 mcg of AOD-9604 per day"; "Published human studies mainly used oral and intravenous forms. Subcutaneous amounts are community research practices, not an approved clinical protocol"	Protocol site, last reviewed August 2026	2026-09-18

The trial doses are milligrams by mouth. The research-vial figures are hundreds of micrograms by injection. The protocol page that publishes the second set states plainly that it does not descend from the first.

Bacteriostatic Water

USP-grade, 0.9% benzyl alcohol, 30 mL multi-dose vial. Research use only.

$30.99

Buy at Medibact

Water per vial and the concentration it gives

The calculator works all three vials at 1, 2 and 3 mL; the protocol page's 5 mg in 3 mL is one of those rows. One U-100 unit is a hundredth of a millilitre (MedlinePlus, "Giving an insulin injection", reviewed 2024-07-21).

Vial	Water added	Concentration	Micrograms per unit
2 mg	1 mL	2 mg/mL	20 mcg
2 mg	2 mL	1 mg/mL	10 mcg
2 mg	3 mL	0.67 mg/mL	6.7 mcg
5 mg	1 mL	5 mg/mL	50 mcg
5 mg	2 mL	2.5 mg/mL	25 mcg
5 mg	3 mL	1.67 mg/mL	16.7 mcg
10 mg	1 mL	10 mg/mL	100 mcg
10 mg	2 mL	5 mg/mL	50 mcg
10 mg	3 mL	3.33 mg/mL	33.3 mcg

A 10 mg vial in 2 mL and a 5 mg vial in 1 mL are the same solution; a 2 mg vial in 2 mL is a quarter of it.

The stated microgram amounts in syringe units

The protocol page states 300 to 500 mcg a day. The table converts both ends of that range at every configuration above.

Vial and water	300 mcg	500 mcg
2 mg in 1 mL	15 units	25 units
2 mg in 2 mL	30 units	50 units
2 mg in 3 mL	45 units	75 units
5 mg in 1 mL	6 units	10 units
5 mg in 2 mL	12 units	20 units
5 mg in 3 mL	18 units	30 units
10 mg in 1 mL	3 units	5 units
10 mg in 2 mL	6 units	10 units
10 mg in 3 mL	9 units	15 units

The spread is the point. The same 300 mcg is 3 units from one configuration and 45 from another, a fifteen-fold difference produced entirely by the vial size and the water. The two vials most easily confused, 2 mg and 5 mg, differ by 2.5 times at any water volume, so a units figure quoted without its vial size is not a figure at all.

The oral trials, and why they do not convert

The only human dose-response data for this compound come from tablets. The 2004 announcement's arms ran from 1 mg to 30 mg a day and the 2006 study's from 0.25 mg to 1 mg; the 2014 review by the developers counts six trials, all oral or intravenous. Those are the figures a reader will find cited as "the clinical dose".

They cannot be carried to a research vial, for two reasons the sources themselves supply. The route is different, and absorption by mouth and by subcutaneous injection are not the same quantity; and the trials measured weight change, not the blood concentrations that a route-to-route conversion would rest on. No published pharmacokinetic bridge exists in the 22 indexed records. The 300 to 500 mcg subcutaneous figures therefore stand on their own as a convention, which is what the protocol page calls them.

The mixing steps, as a label describes them

AOD-9604 has no label. The labelled procedure for a lyophilized peptide supplied with bacteriostatic water is in the EGRIFTA WR (tesamorelin) prescribing information revised in March 2025: only the supplied Bacteriostatic Water for Injection is used; the stated volume is added to the vial; the vial is moved in a circle to mix the powder and liquid and is not shaken; the solution is inspected and not used if particles appear or it is cloudy or coloured. That label also notes that its 11.6 mg in 1.3 mL comes to 8 mg/mL rather than 8.9, because the dissolved powder adds to the final volume, a small correction every calculator, including this site's, ignores. The general procedure for any lyophilized vial is on Medibact's how to reconstitute peptides page and is not repeated here.

Storage after mixing

There is no AOD-9604 label to quote on the solution's storage; what labels and manufacturers state about reconstituted peptides is on Medibact's how to store peptides page.

What this page does not do

It does not state an amount of AOD-9604 to use, a route, a frequency or a course. The 300 to 500 mcg figures are reported because a protocol page states them, with that page's own statement that they are community practice; the oral milligram figures are reported because they are the only human doses that exist, from announcements and a developers' review rather than results papers. The arithmetic converts stated inputs exactly and says nothing about whether any input is appropriate. Medibact's AOD-9604 guide covers the compound; Peptifact's AOD-9604 dosage page counts the literature paper by paper. Decisions about administering anything to a person belong with a clinician.

Sources and dates

Opened 2026-09-18: the DailyMed SPL search API for "AOD-9604" (zero records); the ClinicalTrials.gov v2 API for "AOD-9604" and "AOD9604" as intervention terms (no studies); PubMed through the NCBI E-utilities for AOD9604[tiab] OR "AOD-9604"[tiab] (22 records; 18 with humans[mh]); Moré and Kenley, Journal of Endocrinology and Metabolism 2014;4(3):64-77, doi:10.14740/jem213w; the News-Medical report of 2004-12-16 and the BioSpace announcement of 2006-10-05; the Peptide Dosing Protocols AOD-9604 guide (last reviewed August 2026); the EGRIFTA WR prescribing information (revised 3/2025, sections 2.2 and 11); MedlinePlus, "Giving an insulin injection" (reviewed 2024-07-21). Corrections go to the contact page.

Bacteriostatic Water

USP-grade, 0.9% benzyl alcohol, 30 mL multi-dose vial. Research use only.

$30.99

Buy at Medibact

Medibact Guides facts

AOD-9604 is a synthetic analogue of the C-terminal region of human growth hormone, the fragment at residues 176 to 191 with an added tyrosine. Research vials are 2 mg, 5 mg and 10 mg, the sizes the calculator carries.
No approved product contains AOD-9604 and no trial of it is registered: a DailyMed search on 2026-09-18 returned zero labels, and ClinicalTrials.gov returned no studies for AOD-9604 or AOD9604 as an intervention.
The human trials that exist were oral and intravenous, not subcutaneous. A 2014 review by the compound's developers reports six human trials, two intravenous and two oral pilot studies and two oral Phase IIb studies in 300 and 500 obese adults (Moré and Kenley, Journal of Endocrinology and Metabolism 2014); the same paper reports GRAS status for the compound as a food ingredient.
The developer's own announcements give the oral doses. In December 2004 it reported a 12-week study of 300 obese patients on oral 1, 5, 10, 20 or 30 mg or placebo once daily, with the 1 mg group losing 2.8 kg against 0.8 kg on placebo (reported by News-Medical, 2004-12-16); in October 2006 it described the OPTIONS study of 536 subjects on oral 0.25, 0.5 or 1 mg daily or placebo for 24 weeks (reported by BioSpace, 2006-10-05). Neither is a peer-reviewed results publication.
PubMed held 22 records with AOD9604 or AOD-9604 in the title or abstract on 2026-09-18, 18 of them tagged for humans; the human obesity trials do not appear among them as primary results publications.
The figures protocol pages state for the research vial are 300 to 500 mcg per day subcutaneously. The page opened on 2026-09-18 works a 5 mg vial in 3 mL of bacteriostatic water, about 1,667 mcg/mL, so that 300 mcg is about 18 units and 500 mcg about 30, and states that published human studies mainly used oral and intravenous forms and that subcutaneous amounts are community practice, not an approved protocol (Peptide Dosing Protocols, last reviewed August 2026).
At the calculator's water volumes a 5 mg vial gives 5, 2.5 and 1.67 mg/mL in 1, 2 and 3 mL, so a 300 mcg amount is 6, 12 and 18 units on a U-100 syringe and a 500 mcg amount is 10, 20 and 30; a 2 mg vial in 1 mL is 2 mg/mL, on which 300 mcg is 15 units; a 10 mg vial in 2 mL is 5 mg/mL, on which it is 6 units.
An oral milligram dose does not convert to a subcutaneous microgram figure: the routes differ in absorption, the trials reported weight change rather than blood levels, and no published figure links the 1 mg tablets of the trials to the 300 mcg injections of the protocol pages.
The 2 mg and 5 mg vials look alike and differ by 2.5 times in mass, so a units figure worked for one is wrong for the other by the same factor: at 2 mL of water, 300 mcg is 30 units from a 2 mg vial and 12 units from a 5 mg vial.

Frequently asked questions

How much water goes into a 5 mg vial of AOD-9604?

No label sets it. The protocol page opened on 2026-09-18 works a 5 mg vial at 3 mL of bacteriostatic water, about 1,667 mcg/mL. The calculator's columns give 5 mg/mL at 1 mL, 2.5 mg/mL at 2 mL and 1.67 mg/mL at 3 mL. The volume decides how many units a stated microgram amount occupies; it does not change the 5 mg in the vial, and it is the first thing to confirm before a units figure copied from any page is trusted.

How many units is 300 mcg of AOD-9604 on an insulin syringe?

From a 5 mg vial, 6 units at 1 mL of water, 12 units at 2 mL and 18 units at 3 mL. From a 2 mg vial, 15 units at 1 mL and 30 units at 2 mL. From a 10 mg vial, 3 units at 1 mL, 6 at 2 mL and 9 at 3 mL. A 500 mcg amount is five-thirds of each figure. The same 300 mcg is anything from 3 to 45 units depending on the vial and the water, which is why the concentration has to be stated with the units.

What doses did the human trials of AOD-9604 use?

Oral tablets, and in early work intravenous doses. The developer's announcement of December 2004 describes 300 obese patients on 1, 5, 10, 20 or 30 mg orally once a day for 12 weeks, with the 1 mg group losing 2.8 kg against 0.8 kg on placebo; its October 2006 announcement describes 536 subjects on 0.25, 0.5 or 1 mg daily for 24 weeks. The 2014 review by the developers counts six human trials in all. None was subcutaneous, and none is published as a primary results paper in PubMed.

Why can't the oral trial dose be converted to a subcutaneous figure?

Because nothing published connects them. A tablet and an injection deliver a compound by routes with different absorption, and the trials measured weight change rather than the blood levels that a conversion would need. The protocol page that publishes the 300 to 500 mcg subcutaneous figures says so in its own words: the human studies were oral and intravenous, and the subcutaneous amounts are community practice. The arithmetic on this page converts micrograms to units; it cannot convert a route.

Is AOD-9604 approved or in a registered trial?

Neither. DailyMed holds no AOD-9604 label and ClinicalTrials.gov holds no study of it under either spelling, as of 2026-09-18. The developers' 2014 paper reports that the compound received GRAS status, generally recognised as safe, for its intended use in foods and supplements, which is a food-ingredient designation and not a drug approval, and says nothing about injection. The subcutaneous research vial has no regulatory document of any kind behind it.

How is AOD-9604 reconstituted?

As labels describe for any lyophilized peptide, since it has no label of its own. The EGRIFTA WR label, revised March 2025, has the stated volume of bacteriostatic water added to the vial, the vial moved in a circle to mix rather than shaken, and the solution inspected and used only if clear and free of particles. The general procedure is on Medibact's reconstitution page; this page carries the arithmetic for the three vial sizes.